Impact of postoperative adjuvant therapy timing on oncologic outcomes in esophageal cancer following neoadjuvant treatment

We evaluated whether the interval from esophagectomy to postoperative adjuvant therapy (time to adjuvant therapy [TTAT]) was associated with disease-free survival (DFS), overall survival (OS), and adverse events after neoadjuvant treatment for esophageal cancer. This retrospective cohort included 177 patients who received 2–4 cycles of postoperative chemotherapy plus immune-checkpoint inhibition followed by maintenance immunotherapy after neoadjuvant treatment and esophagectomy. Eligibility required completion of the defined postoperative treatment sequence; patients receiving nonconforming regimens were excluded. Follow-up data were current through September 10, 2026. Patients were classified as TTAT ≤ 56 days ( n = 97) or > 56 days ( n = 80). Multivariable Cox models and propensity-score matching (PSM) were used to evaluate the association between TTAT and outcomes. Median follow-up was 42.3 months. There were 71 DFS events (28/97 versus 43/80) and 46 deaths (13/97 versus 33/80). Two-year DFS was 81.4% versus 70.0% (adjusted hazard ratio [HR] for > 56 versus ≤ 56 days, 2.31; 95% confidence interval [CI], 1.39–3.87; P = 0.001), and two-year OS was 91.8% versus 85.0% (adjusted HR, 3.09; 95% CI, 1.57–6.11; P = 0.001). After matching 64 patients per group, the corresponding HRs were 1.81 (95% CI, 1.00-3.26; P = 0.048) for DFS and 2.97 (95% CI, 1.33–6.65; P = 0.008) for OS. The overall incidence of recorded adverse events did not differ significantly between the two groups (72.2% versus 81.3%; P = 0.157). Among patients who received neoadjuvant treatment, esophagectomy, and a uniform postoperative chemoimmunotherapy followed by maintenance strategy, initiation of postoperative therapy within 56 days was independently associated with longer DFS and OS. The consistency of the multivariable, continuous-TTAT, and propensity-matched analyses indicates that TTAT carries prognostic information in this population. These findings support avoiding preventable postponement once postoperative recovery is adequate, but residual confounding and the retrospective design preclude causal interpretation or use of 56 days as a universal treatment threshold.

Authors

Institutions

Publication Details

Journal
BMC Gastroenterology
Published
2026-11-17
DOI
https://doi.org/10.1186/s12876-026-05501-1
Primary Topic
Esophageal Cancer Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Impact of postoperative adjuvant therapy timing on oncologic outcomes in esophageal cancer following neoadjuvant treatment

Zhengchao Xu, Wang Lv, Muhu Tang, Yueli Rao et al.
BMC Gastroenterology
Esophageal Cancer Research and Treatment
article

Impact of postoperative adjuvant therapy timing on oncologic outcomes in esophageal cancer following neoadjuvant treatment

Zhengchao Xu, Wang Lv, Muhu Tang, Yueli Rao, Jiacong Liu, Peng Ye, Xu Lin, Luming Wang, Jian Hu, Minghua Ye
article en

Abstract

We evaluated whether the interval from esophagectomy to postoperative adjuvant therapy (time to adjuvant therapy [TTAT]) was associated with disease-free survival (DFS), overall survival (OS), and adverse events after neoadjuvant treatment for esophageal cancer. This retrospective cohort included 177 patients who received 2–4 cycles of postoperative chemotherapy plus immune-checkpoint inhibition followed by maintenance immunotherapy after neoadjuvant treatment and esophagectomy. Eligibility required completion of the defined postoperative treatment sequence; patients receiving nonconforming regimens were excluded. Follow-up data were current through September 10, 2026. Patients were classified as TTAT ≤ 56 days ( n = 97) or > 56 days ( n = 80). Multivariable Cox models and propensity-score matching (PSM) were used to evaluate the association between TTAT and outcomes. Median follow-up was 42.3 months. There were 71 DFS events (28/97 versus 43/80) and 46 deaths (13/97 versus 33/80). Two-year DFS was 81.4% versus 70.0% (adjusted hazard ratio [HR] for > 56 versus ≤ 56 days, 2.31; 95% confidence interval [CI], 1.39–3.87; P = 0.001), and two-year OS was 91.8% versus 85.0% (adjusted HR, 3.09; 95% CI, 1.57–6.11; P = 0.001). After matching 64 patients per group, the corresponding HRs were 1.81 (95% CI, 1.00-3.26; P = 0.048) for DFS and 2.97 (95% CI, 1.33–6.65; P = 0.008) for OS. The overall incidence of recorded adverse events did not differ significantly between the two groups (72.2% versus 81.3%; P = 0.157). Among patients who received neoadjuvant treatment, esophagectomy, and a uniform postoperative chemoimmunotherapy followed by maintenance strategy, initiation of postoperative therapy within 56 days was independently associated with longer DFS and OS. The consistency of the multivariable, continuous-TTAT, and propensity-matched analyses indicates that TTAT carries prognostic information in this population. These findings support avoiding preventable postponement once postoperative recovery is adequate, but residual confounding and the retrospective design preclude causal interpretation or use of 56 days as a universal treatment threshold.

BMC Gastroenterology
Blood Center of Zhejiang Province (CN), First Affiliated Hospital Zhejiang University (CN), Zhejiang University (CN)
Esophageal Cancer Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon